8-K

- --------------------------------------------------------------------------------
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  ------------

                                    FORM 8-K

                                  ------------

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): July 26, 2006

                                  ------------

                         Diagnostic Products Corporation
             (Exact name of registrant as specified in its charter)

                                  ------------


           California                1-9957                95-2802182
 (State or other jurisdiction of   (Commission           (I.R.S. Employer
 incorporation or organization)    File Number)        Identification No.)


           5210 Pacific Concourse Drive, Los Angeles, California 90045
               (Address of principal executive offices) (Zip code)

       Registrant's telephone number, including area code: (310) 645-8200

                                 Not Applicable
          (Former name or former address, if changed since last report)

                                  ------------

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

|_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

- --------------------------------------------------------------------------------



Item 8.01. Other Events.

     On July 26, 2006, Diagnostic Products Corporation (the "Company") issued a
press release announcing that plaintiffs in their pending shareholder derivative
action, Nicholas Weil, City of Tamarac General Employees' Pension Trust Fund and
City of Tamarac Police Officers' Pension Trust Fund, have filed a first amended
complaint in the United States District Court of the Central District of
California, Case No. CV06-00066DDP. A copy of the Company's press release is
being furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by
reference in its entirety.


Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit
Number     Description of Exhibit
- ------     ----------------------

99.1       Press release issued by Diagnostic Products Corporation on July 26,
           2006.







                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                       DIAGNOSTIC PRODUCTS CORPORATION


Dated: July 26, 2006                   By:  /s/ James L. Brill
                                            ------------------------------------
                                       Name:  James L. Brill
                                       Title: Vice President, Finance and
                                              Chief Financial Officer

EX-99.1

                                                                    Exhibit 99.1

 Diagnostic Products Corporation Announces Plaintiffs in Shareholder
         Derivative Action Have Filed First Amended Complaint

    LOS ANGELES--(BUSINESS WIRE)--July 26, 2006--Diagnostic Products
Corporation (NYSE:DP) announced today that plaintiffs in their pending
shareholder derivative action, Nicholas Weil, City of Tamarac General
Employees' Pension Trust Fund and City of Tamarac Police Officers'
Pension Trust Fund, have filed a first amended complaint in the United
States District Court of the Central District of California, Case No.
CV06-00066DDP. The amended complaint challenges the proposed merger of
DPC with a wholly owned subsidiary of Siemens Medical Solutions USA,
for a number of reasons, including on the basis of fairness of price,
disclosure and conflicts of interest. The amended complaint seeks to
enjoin or rescind the proposed merger. The Company believes that the
claims are without merit and intends to vigorously defend itself in
this case.

    About Diagnostic Products Corporation

    Diagnostic Products Corporation, founded in 1971, is a leader in
the global in vitro diagnostics market. DPC's product offering
includes the widely accepted IMMULITE(R) series of immunoassay
systems, more than 75 immunoassays and an expanding menu of essential
specific allergens and allergy panels that are run just like other
immunoassays. DPC also designs and manufactures automated laboratory
instrumentation and automation solutions that provide fast, accurate
results while enabling our customers to do "more with less" in a
leaner laboratory. DPC's combined chemistry and immunoassay menu is
one of the largest and most diversified available, covering most
laboratory tests requested. In fiscal 2005 (December 31), DPC reported
sales of $481 million and income from operations of $96 million.
Additional information can be found on DPC's website at
www.dpcweb.com.

    CONTACT: Diagnostic Products Corporation
             James L. Brill, 310-645-8200
             Chief Financial Officer